Report
Dylan Van Haaften

SENSORION: Decibel data sets a high bar for CIO, but also reflects complexities in administration | CORPORATE | EUR4.8

SENSORION - CORPORATE | EUR4.8
Decibel data sets a high bar for CIO, but also reflects complexities in administration

Data was good and sets a high bar …
… but safety leaves plenty to be desired, we cannot rule out SENS-401 for CIO
Underlying
Sensorion SAS

Sensorion SA is a France-based company principally engaged in the biopharmaceutical sector. The Company is principally active in the development of targeted therapeutic solutions to treat inner ear diseases. The Company develops also drug treatments, from molecular biology all the way to animal pharmacology, toxicology, and clinical research and therapeutic solutions to treat vestibular deficits. Sensorion SA is a spin-off of the research team Pathophysiology and Therapy of Vestibular Deficits in Montpellier Neuroscience Institute.

Provider
Bryan Garnier
Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Analysts
Dylan Van Haaften

Other Reports on these Companies
Other Reports from Bryan Garnier

ResearchPool Subscriptions

Get the most out of your insights

Get in touch